Reprogramming cell fates towards novel cancer immunotherapies

ElsevierVolume 67, December 2022, 102312Current Opinion in PharmacologyAbstract

Recent advances in our understanding of host immune and cancer cells interactions have made immunotherapy a prominent choice in cancer treatment. Despite such promise, cell-based immunotherapies remain inapplicable to many patients due to severe limitations in the availability and quality of immune cells isolated from donors. Reprogramming technologies that facilitate the engineering of cell types of interest, are emerging as a putative solution to such challenges. Here we focus on the recent progress being made in reprogramming technologies with respect to the immune system and their potential for clinical applications.

View full text

© 2022 Elsevier Ltd. All rights reserved.

留言 (0)

沒有登入
gif